Madrigal pharmaceuticals, inc. (MDGL)
CashFlow / Quarterly
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14Dec'13Sep'13Jun'13Mar'13Dec'12Sep'12Jun'12Mar'12Dec'11Sep'11Jun'11Mar'11
Cash flows from operating activities:
Net loss

-36,135

-27,740

-21,429

-19,699

-15,080

-11,475

-8,512

-6,460

-6,364

-8,445

-8,363

-8,347

-5,999

-7,749

-14,049

-2,877

-1,713

-10,536

-17,628

-19,800

-20,707

-20,352

-19,966

-22,286

-23,557

-24,162

-22,515

-22,787

-20,728

-18,123

-14,996

-14,620

-15,051

-10,743

-12,734

-12,502

-11,401

Adjustments to reconcile net loss to net cash used in operating activities:
PIK interest expense on convertible promissory notes payable - related parties

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

237

970

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Stock-based compensation expense

4,846

4,032

4,950

7,755

6,022

5,119

4,976

2,227

1,167

947

1,029

676

602

-

-

-

-

579

1,168

843

1,710

1,766

1,566

1,513

2,586

1,540

1,683

1,591

1,216

963

801

731

827

848

867

812

827

Depreciation and amortization expense

125

28

28

28

28

25

24

24

23

-

-

-

-

-

-

-

-

159

166

168

169

169

167

169

168

143

148

125

100

115

170

223

230

291

350

384

439

Changes in operating assets and liabilities:
Accounts receivable - related parties

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

-7

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Collaboration receivable

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

-116

Prepaid expenses and other current assets

-175

-561

-677

1,794

-888

717

278

293

-290

-212

-287

517

-520

-1,008

-940

555

103

-774

-238

846

-289

-1,255

647

659

-153

-593

-279

162

689

-17

-36

231

47

-801

530

308

93

Other assets

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-226

-52

-286

259

-26

-27

-26

-32

976

-31

-17

23

-8

-37

-16

-112

101

33

80

51

Accounts payable

-63

405

327

-3,930

1,889

1,456

443

-832

-509

279

115

-1,495

2,018

-398

-259

161

368

-125

-1,594

-719

598

-1,303

-784

-583

-780

896

472

-498

58

1,971

222

428

-427

545

923

308

-234

Accrued expense

632

8,359

2,817

5,786

-179

346

763

-26

-3,251

1,002

1,972

2,025

-912

1,283

-3,978

386

28

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Accrued interest, net of interest received on maturity of investments

-86

2,073

1,306

314

-46

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Accrued interest - related party

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

1

5

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net cash used in operating activities

-30,506

-12,282

-11,324

-11,540

-6,478

-6,265

-5,238

-5,360

-8,644

-5,945

-4,951

-7,650

-3,771

-5,280

-9,243

-2,647

-438

-19,337

-15,602

-17,730

-18,775

-19,215

-18,566

-20,874

-20,270

-18,690

-16,588

-19,919

-22,214

-12,523

-13,263

-13,095

-15,254

-10,486

-11,821

-12,154

-12,839

Cash flows from investing activities:
Accrued contract research costs

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-10,343

2,478

2,217

194

-1,959

1,289

499

2,081

2,055

2,441

1,010

140

1,042

-57

-231

1,166

-169

139

-382

742

Other accrued liabilities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-71

-482

121

-769

1,183

-218

447

-953

1,221

873

785

-2,288

1,484

524

589

-2,064

1,345

340

757

-2,042

Deferred collaboration revenue

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-3,303

-1,143

-1,143

-1,142

Purchases of marketable securities

58,647

212,230

140,957

92,279

173,837

89,423

273,066

129,676

122,193

35,301

3,797

8,994

22,119

-

-

-

-

24,659

13,553

50,240

28,683

25,335

50,795

14,167

3,548

42,968

9,899

5,994

55,290

4,146

23,130

-67

22,824

3,732

7,331

25,129

14,534

Sales and maturities of marketable securities

109,421

181,857

169,222

128,716

170,387

114,419

51,051

48,763

20,071

41,386

-13,089

8,470

11,563

-

-

-

-

35,759

37,186

27,248

37,000

24,464

15,250

25,670

19,768

27,900

18,408

25,009

18,950

10,750

16,500

3,695

9,650

24,101

14,302

11,000

11,342

Purchases of property and equipment, net of disposals

314

134

-2

-1

41

8

13

0

1

0

0

123

2

-

-

-

-

-

-

-

-

59

37

25

23

82

16

395

276

84

209

65

147

382

263

35

10

Net cash provided by (used in) investing activities

50,460

-30,507

28,267

36,438

-3,491

24,988

-222,028

-80,913

-102,123

6,085

-16,886

-647

-10,558

-

-

-

-

11,082

23,620

-23,019

8,317

-930

-35,582

11,478

16,197

-15,150

8,493

18,620

-36,616

6,520

-6,839

3,697

-13,321

19,987

6,708

-14,164

-3,202

Cash flows from financing activities:
Proceeds from the sale of related party stock and exercise of common stock options, net of transaction costs

0

-

-

-

83

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Proceeds from the sale of related party stock and exercise of common stock options, net of transaction costs

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

22,786

25,759

0

5,000

-

-

-

-

Proceeds from the exercise of common stock options

-

-

-

-

-

-

451

1,184

265

-

-

-

3,399

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Proceeds from issuance of common stock, net of transaction costs

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

1

28,122

51,555

10,118

37,653

11

26

1,045

37,288

158

598

28,204

-

-

-

-

Proceeds from convertible notes - related parties

-

-

-

-

-

-

-

-

-

-

-

-

-

0

1,625

6,125

750

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Proceeds from issuance of common stock, excluding to related parties, and exercise of common stock options, net of transaction costs

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

190

Proceeds from term loans

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

290

13,210

-

-

-

-

0

0

0

2,000

Payment of term loans

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

2,306

2,304

2,303

2,301

2,299

2,297

2,364

2,490

234

218

193

1,972

1,966

1,962

155

151

-

-

-

-

Payment of capital lease obligations

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

11

11

10

10

11

10

10

11

3

4

3

3

3

4

2

3

11

14

89

87

Net cash provided by financing activities

0

0

35

117

83

610

451

313,009

265

135,527

0

34,879

3,399

5,954

1,625

6,125

750

-2,316

5,516

39,497

-2,311

-2,309

25,815

54,173

7,617

56,853

-211

120

12,280

58,073

23,951

441

33,050

-69

-135

34,837

2,103

Net increase (decrease) in cash and cash equivalents

19,954

-42,789

16,978

25,015

-9,886

19,333

-226,815

226,736

-110,502

135,667

-21,837

26,582

-10,930

10,752

4,297

3,478

312

-10,571

13,534

-1,252

-12,769

-22,454

-28,333

44,777

3,544

23,013

-8,306

-1,179

-46,550

52,070

3,849

-8,957

4,475

9,432

-5,248

8,519

-13,938

Supplemental disclosure of cash flow information:
Obtaining a right-of-use asset in exchange for a lease liability

0

0

0

0

900

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Cash paid for interest

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

152

213

267

325

377

443

495

560

594

596

533

789

361

428

422

485

427

652

461

371